Anavex Life Sciences Corp. (NASDAQ:AVXL) has been given a consensus recommendation of “Buy” by the seven analysts that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation and six have given a buy recommendation to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $33.83.
AVXL has been the subject of several research reports. BTIG Research reiterated a “buy” rating and set a $34.00 price target on shares of Anavex Life Sciences in a research report on Thursday, November 25th. Zacks Investment Research cut Anavex Life Sciences from a “hold” rating to a “sell” rating in a report on Wednesday, January 26th. Finally, HC Wainwright reiterated a “buy” rating and set a $39.00 price target on shares of Anavex Life Sciences in a report on Thursday, October 14th.
Shares of AVXL opened at $13.08 on Tuesday. Anavex Life Sciences has a one year low of $6.25 and a one year high of $31.50. The stock has a market capitalization of $994.32 million, a price-to-earnings ratio of -24.68 and a beta of 0.57. The stock has a 50 day moving average price of $16.67 and a 200 day moving average price of $18.29.
Anavex Life Sciences (NASDAQ:AVXL) last issued its quarterly earnings results on Wednesday, November 24th. The biotechnology company reported ($0.15) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.15). During the same period in the previous year, the firm earned ($0.10) EPS. Sell-side analysts predict that Anavex Life Sciences will post -0.44 EPS for the current year.
This Emerging Biotech Company is Working to Create Shareholder Value!
Several hedge funds have recently made changes to their positions in AVXL. Saturna Capital CORP lifted its holdings in shares of Anavex Life Sciences by 3.8% in the 3rd quarter. Saturna Capital CORP now owns 13,600 shares of the biotechnology company’s stock valued at $244,000 after buying an additional 500 shares during the period. Commonwealth Equity Services LLC lifted its holdings in shares of Anavex Life Sciences by 1.3% in the 3rd quarter. Commonwealth Equity Services LLC now owns 42,315 shares of the biotechnology company’s stock valued at $759,000 after buying an additional 546 shares during the period. UBS Asset Management Americas Inc. lifted its holdings in shares of Anavex Life Sciences by 0.8% in the 3rd quarter. UBS Asset Management Americas Inc. now owns 68,751 shares of the biotechnology company’s stock valued at $1,234,000 after buying an additional 567 shares during the period. SeaCrest Wealth Management LLC lifted its holdings in shares of Anavex Life Sciences by 4.7% in the 3rd quarter. SeaCrest Wealth Management LLC now owns 14,475 shares of the biotechnology company’s stock valued at $260,000 after buying an additional 650 shares during the period. Finally, AQR Capital Management LLC raised its holdings in Anavex Life Sciences by 2.7% during the second quarter. AQR Capital Management LLC now owns 29,195 shares of the biotechnology company’s stock worth $667,000 after purchasing an additional 776 shares during the last quarter. Institutional investors own 27.38% of the company’s stock.
Anavex Life Sciences Company Profile
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer’s and Parkinson’s disease and central nervous system diseases, including Rett syndrome.
Read More: Marijuana Stocks Investing Considerations
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Should you invest $1,000 in Anavex Life Sciences right now?
Before you consider Anavex Life Sciences, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Anavex Life Sciences wasn’t on the list.
While Anavex Life Sciences currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The 5 Stocks Here
Be the first to comment